Review Papers Claim by Claim

Check each claim against its experiments, reported results, scope, and stated limitations.Know what the science actually supports before you trust the answer.

Press Enter ↵ to start review

Explore by Goal

Quick Explanation Copied

Yes — the reviewed document is the review article itself: Hubbard's "Structure-based drug discovery and protein targets in the CNS" (Neuropharmacology, 2011; DOI 10.1016/j.neuropharm.2010.07.016), a single-author, 127-reference survey rather than a primary experimental study ().

Long Explanation

Document type confirmed

Yes, the paper under review is the review itself. The supplied full text is a single-author narrative review by Roderick E. Hubbard (Vernalis R&D and the University of York), received June 2010, accepted July 2010, published in Neuropharmacology (). It contains no new experiments; its original contribution is the survey of methods (crystallography, NMR, SPR, ITC/DSF, docking, fragment-based discovery) plus a census of 879 CNS clinical trials, of which 596 were small-molecule trials with defined targets, categorized into five structural-knowledge tiers ().

This is why the prior critique scored it as a review: originality comes from synthesis (novelty 6/10) rather than data, reproducibility is limited by reliance on the proprietary MedTrack database (5/10), and self-citation of the author's own work (estrogen receptor, Hsp90, fragment library design) is a notable feature of the reference list (). No evaluation change is needed — the prior review was already framed as a critique of the review article itself.

Feedback:

Updated: October 10, 2026

BGPT Paper Review

Study Novelty

60%

A 2010 synthesis: fragment-based and GPCR structures were hot topics, but no single novel method or dataset; its value is the CNS-target census, which was reasonably fresh at publication.

Scientific Quality

70%

Accurate, honest about docking/scoring limits, and well-referenced (127 refs), but single-authored, partly self-promotional (own Hsp90/estrogen receptor work), proprietary MedTrack source, no quantitative validation, and no formal COI statement in the provided text.

Study Generality

60%

Methods discussion generalizes beyond CNS, but the target census is a 2010 snapshot tied to one commercial trial database; conclusions are qualitative.

Study Usefulness

70%

A useful roadmap for applying structure-based methods to CNS membrane proteins; its cautionary BACE/CNS-property discussion (MW ~319, clogP 3.4, PSA 41) remains practically relevant, though half its content is now superseded.

Study Reproducibility

50%

As a review, no new data; the trial census depends on proprietary MedTrack access and ad hoc classification criteria that are only loosely defined, limiting independent replication.

Explanatory Depth

70%

Mechanistic explanation of each biophysical method, entropy/enthalpy tradeoffs, GPCR stabilization strategies, and why scoring functions fail (ΔG as a small difference between large numbers) shows real practitioner insight.

🎁 Authors: Collect 123 Free Science Tokens (≈ $12.3 USD)

Claim My Author Tokens

Use for 30 days of free BGPT access (4 tokens = 1 day) or trade/sell (≈ $12.3 USD)

Top Data Sources Export MCP

1. Structure-based drug discovery and protein targets in the CNS [2011]

8QualityResults Limitations Context Blindspots Methods

↗ Paper Review ↗ Full Paper

2. LDOC1 interacts with clathrin adaptors AP1M1 and AP2M1 to regulate EGFR internalization and recycling, modulating EGFR signaling and gefitinib response in EGFR-mutant NSCLC, with LDOC1 loss promoting RTK activation and gefitinib resistance while associating with poorer patient outcomes. [2024]

9QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

3. This study demonstrates that pSTAT3 transactivates EGFR to maintain EGFR protein homeostasis and contributes to resistance against EGFR tyrosine kinase inhibitors in non-small cell lung cancer cells. [2024]

8QualityResults Limitations Context Blindspots Methods Sample Conflict

↗ Paper Review ↗ Full Paper

4. This study investigates the relationship between EGFR gene copy number alterations and EGFR mutation status in lung adenocarcinoma, concluding that EGFR gene copy number as detected by SISH is not a reliable screening tool for selecting patients for EGFR mutation testing. [2014]

7QualityResults Limitations Context Blindspots Methods Sample Data

↗ Paper Review ↗ Full Paper

5. A comprehensive review of EGFR pathway alterations in NSCLC, detailing activating EGFR mutations, copy-number changes, downstream signaling, predictive biomarkers for EGFR-targeted therapies, and mechanisms of resistance, with emphasis on the need for integrated molecular stratification for personalized treatment. [2011]

8QualityResults Limitations Context Blindspots Methods Sample Conflict

↗ Paper Review ↗ Full Paper

Key Insight

Because the artifact is a review, its scientific worth rests entirely on calibration of predictions, not data — and its most durable element is the honest quantification of docking failure modes and the BACE caution, which anticipated a class-wide clinical failure.

Keep Exploring

Which specific CNS GPCR targets from the review's Category 2 and 3 lists have since yielded clinically approved drugs via structure-based design, and does the review's category scheme predict those successes?

How did the cryo-EM revolution after 2015 change the distribution of CNS targets across the review's five structural-knowledge categories, and which categories were eliminated entirely?

Hypothesis Graveyard

Structure availability alone unlocks CNS discovery — partially falsified: BACE had abundant structures and fragments yet no approved inhibitor emerged within a decade of the review.

Homology models suffice for GPCR design — substantially superseded: post-2011 experimental structures showed model error in extracellular loops where many ligands bind.

Potential Experiments

Retrospective cohort analysis correlating the review's five structure categories with 2010–2025 CNS approval outcomes to quantify whether Category 5 targets yield drugs more often — directly testing the review's central premise.

Prospective head-to-head: fragment screening plus structures versus HTS on the same CNS membrane protein (e.g., an ion channel), measuring hit-to-lead progression rates under matched CNS-property constraints.

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

As a computational-science-oriented reviewer I may overweight methodological honesty (docking limits) and underweight the review's historical significance to practitioners of the era.

Stay current without chasing every paper.

Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.

My BGPT

Trending